Advocacy Track EHA19

 

Advocacy Track EHA19

After a successful introduction of the EHA Advocacy track at last year’s EHA Annual Congress, the congress program was again complemented this year by a dedicated advocacy track. This track combines all patient and policy related sessions into one, comprehensive yet very diverse, full-day program. To enable a continuing discussion of the interesting and important topics discussed, the webcasts of these sessions are now freely available to all.

The two Patient Advocacy Sessions provide an opportunity for patients suffering from blood disorders to discuss with hematologists issues of common concern. The first Patient Advocacy Session relates to the quality of generic issues from diferent perspectives. The second session deals with the challenges of young patients with old people’s diseases.

The interactive EHA/ESH Joint Symposium deals, again, with how to you explain to a patient that he/she can not receive treatment. This time, a mock consult combining intercultural communication and clinical trial eligibility criteria provided for an educational performance.

The EHA/ASH Joint Symposium touches upon the highly controversial issue of pricing of innovative medicines. The president of the European trade organization of the pharmaceutical industry and the president of the Haute Autorité de Santé exchange their views. 

Lastly, EHA’s own advocacy session concerns the important issue of the future of hematologic research in Europe. EHA is initiating the creation of a Research Roadmap for Blood Disorders in Europe. This project is presented here and together with comments from the perspectives of personalized medicines, Horizon 2020 and patients.

Not all videos are available at this time. They will become available over the next few weeks.

 

Patient Advocacy Session 1 pt. 1 (Generics in Hematology)
Patient Advocacy Session 1 pt. 2 (The challenges of young patients with old people’s disease)
The EHA Advocacy Session 5 (The Future of Hematological Research in Europe)

Patient Advocacy Session 1 (Generics in Hematology)
Patient Advocacy Session 2 (The challenges of young patients with old people’s disease)
EHA-ASH Joint Symposium Session 4 (Access to medicines and fair pricing)
EHA Advocacy Session (The Future of Hematological Research in Europe)